2026-10-19T01:08:41Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/198572026-10-18T21:11:53Zopenairedrivercom_ebyu_10000col_ebyu_10001

Microorganisms Causing Ventilator-Associated Pneumonia and Their Antibiotic Susceptibilitykarakeçili, farukKaravaş, Erdalünver, edhemÇIKMAN, AYTEKİNBinay, Umut DevrimKOÇ, ALPARSLANMikrobiyolojiSağlık Bilimleri ve HizmetleriYoğun BakımTıpObjectives: The aim of this study was to determine the microorganisms causing ventilator-associated pneumonia(VAP) and investigate their antibiotic susceptibility.Methods: Patients diagnosed with VAP in the adult intensive care units (ICUs) between January 2015 and December2018 were included in the study. VITEK 2 (bioMérieux, Marcy l’Etoile, France) automated microbiology system was usedto identify microorganisms and to determine their antibiotic susceptibility.Results: Average VAP rates was found 26.51 per 1000 ventilator-days. A single microorganism was isolated in 104 ofa total of 105 patients while two microorganisms were isolated in 1 patient. Of the isolated microorganisms, 94.3%(n=100) were Gram-negative bacteria and 5.7% (n=6) were Gram-positive bacteria. When the distribution of all microorganisms is examined in order of frequency, 62.2% were found to be Acinetobacter spp., 17.9% Pseudomonas spp., 6.6%Klebsiella pneumoniae, 4.7% Staphylococcus aureus, 3.7% Serratia marcescens, 2.8% Escherichia coli, 0.9% Enterococcusfaecium, and 0.9% Stenotrophomonas maltophilia. The most effctive antibiotics against Acinetobacter spp. were foundto be colistin (96.9%), tigecycline (95%), amikacin (15%) and gentamicin (5%), whereas those the most effctive againstPseudomonas spp. were found to be colistin (94.1%), ceftazidime (57.8%), gentamicin (55.5%), ciproflxacin (50%), amikacin(50%), and piperacillin/tazobactam (42.1%).Conclusion: Acinetobacter spp. was the most common agent in VAP. The fact that Acinetobacter spp., which is resistantto carbapenems, quinolones, piperacillin-tazobactam and cephalosporins, was the most common agent in VAP, cansignifiantly affct the mortality rate of the infection2019Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/19857https://doi.org/10.14744/ejmi.2019.14976enEurasian Journal of Medical Investigationinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/19857